To observe the effects of multi-glycosides of tripterygium wilfordii in the treatment of idiopathic membranous nephropathy, and to explore the effects on anti-phospholipase A2 receptors (Anti-PLA2R). Methods:A total of 68 patients with idiopathic membranous nephropathy in our hospital from November 2013 to December 2015 were selected and randomly divided into observation group and control group by random number table. Two groups of patients were given primary symptomatic treatment. The control group was given prednisone and cyclophosphamide, and the treatment group was treated with oral administration of multi-glycosides of tripterygium wilfordii. The treatment last for 12 weeks. 24h urinary protein, serum albumin (ALB), blood urea nitrogen (BUN), serum creatinine (SCr), serum PLA2R expression of all patients before treatment, and 12 weeks after treatment were evaluated. Results:After 12 weeks of treatment, 24h urine protein, BUN, CREA of patients were significantly decreased after treatment (P<0.05), but there was no significant difference between treatment group and control group (P<0.05). After treatment, ALB of both groups was significantly increased. Compared with before treatment, there was statistically significant difference (P<0.05), but there was no significant difference between two groups (P<0.05). The expression of serum Anti-PLA2R of two groups was significantly decreased after treatment, and the treatment groups was significantly better than the control group (P<0.05). Conclusion:Multi-glycosides of tripterygium wilfordii has similar efficacy with prednisone combined with cyclophosphamide, which can effectively improve renal function of patients with idiopathic membranous nephropathy, relieve clinical symptoms and signs. Multi-glycosides of tripterygium wilfordii has less side effects, and is worthy of clinical research.